Li Xu

Dr. Li Xu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
YJYa-Nan Jia
Ya-Nan Jia
HLHai-Peng Lu
Hai-Peng Lu
YPYa-Lin Peng
Ya-Lin Peng
BZBao-Shun Zhang
Bao-Shun Zhang
XGXiao-Bao Gong
Xiao-Bao Gong
LXLi Xu
Li Xu

11 October 2017 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
HLHai‐Peng Lu
Hai‐Peng Lu
YJYa‐Nan Jia
Ya‐Nan Jia
YPYa‐Lin Peng
Ya‐Lin Peng
YYYan Yu
Yan Yu
SSSi‐Long Sun
Si‐Long Sun
LXLi Xu
Li Xu

20 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
YZYou Zhou
You Zhou
XLXin Lu
Xin Lu
HYHongyu Yang
Hongyu Yang
YCYao Chen
Yao Chen
Feng WangFeng Wang
Feng Wang
QXQingyou Xia
Qingyou Xia
As there are increased levels and activity of butyrylcholiesterase (BChE) in the late stage of Alzheimer’s disease (AD), development of selective BChE inhibitors is of vital importance. In this study, a workflow combining computational technologies and biological assays were implemented to identify selective BChE inhibitors with new chemical scaffolds. In particular, a pharmacophore model served as a 3D search query to screen three compound collections containing 3.0 million compounds. Molecular docking and cluster analysis were performed to increase the efficiency and accuracy of virtual screening. Finally, 15 compounds were retained for biological investigation. Results revealed that compounds 8 and 18 could potently and highly selectively inhibit BChE activities (IC50 values < 10 μM on human BChE, selectivity index BChE > 30). These active compounds with novel scaffolds provided us with a good starting point to further design potent and selective BChE inhibitors, which may be beneficial for the treatment of AD.

23 April 2019 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
YJYa-Nan Jia
Ya-Nan Jia
YPYa-Lin Peng
Ya-Lin Peng
YZYi-Ping Zhao
Yi-Ping Zhao
XCXi-Fei Cheng
Xi-Fei Cheng
YZYou Zhou
You Zhou
LXLi Xu
Li Xu

3 December 2022 in GeroScience
Verified
Journal Article
Closed access
PDF file
PXPingkang Xu
Pingkang Xu
QCQimin Chen
Qimin Chen
XCXiaoman Chen
Xiaoman Chen
HQHao Qi
Hao Qi
YYYuyan Yang
Yuyan Yang
ZWZiyun Wu
Ziyun Wu

2 November 2021 in Foods
Verified
Journal Article
Open access
PDF file
WXWei Xiang
Wei Xiang
ZXZhining Xia
Zhining Xia
LXLi Xu
Li Xu
As a by-product in the sericulture industry, mulberry branches are not currently utilized effectively. Jialing 20 is an artificial triploids mulberry that widely cultivated in southwest China. In this study, the chemical composition of the Jialing 20 mulberry branch extract (MBE) was first analyzed by UPLC-MS/MS, and 42 components, including alkaloids, flavonoids, and coumarins, were obtained. Then, the antioxidant activities, hypoglycemic effect, Alzheimer’s disease inhibition, and cardiovascular protection of MBE were also evaluated in vitro. The IC50 values for the scavenging DPPH and ABTS radicals were, respectively, 31.23 ± 0.57 μg/mL and 8.88 ± 0.36 μg/mL (IC50 values of positive Vc were, respectively, 4.41 ± 0.19 μg/mL and 8.79 ± 0.41 μg/mL). The IC50 value for inhibiting α-glucosidase was 1.90 ± 0.05 μg/mL (IC50 value of positive acarbose was 0.03 μg/mL). The IC50 values for inhibiting acetylcholinesterase and butyrylcholinesterase were, respectively, 179.47 ± 0.38 μg/mL and 101.82 ± 3.37 μg/mL (IC50 values of positive berberine were, respectively, 1.27 ± 0.03 μg/mL and 57.41 ± 0.21 μg/mL). MBE (10 μg/mL and 40 μg/mL) significantly increased the survival rate of oxidized low-density lipoprotein- (ox-LDL) induced human umbilical vein endothelial cells (HUVECs) and significantly decreased the intracellular reactive oxygen species. These results suggest that the extracts of Jialing 20 mulberry branches could be used as a functional food additive.